PREPARE STUDY: PRevalence of the Eosinophilic Phenotype Among SeveRE Asthma Patients in AstraZeneca International Region. A Multinational, Cross-Sectional, Multicenter Study

CompletadoClinicalTrials.gov

ID: NCT03931954Tipo: OBSERVATIONALInicio: 15 de may de 2019Fin estimado: 26 de nov de 2020

Traducción no disponible, mostrando original

Resumen

The purpose of this cross-sectional, multicenter study is to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients who attend to sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and asthma control, will also be studied.

Descripción detallada

To determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients attending their routine clinical visit at sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and the status of asthma control, will also be studied. It is expected that this study will contribute to the understanding of severe asthma, ultimately helping to inform therapeutic decisions and addressing patients' needs.

Elegibilidad

Sexo: ALL

Criterios de inclusión

Male or female patient, aged 12 years or older by the time of study entry
Patient visiting a participating center for a routine clinical appointment
Patient is willing and able to provide a blood sample for IgE and eosinophil levels determination as part of their routine clinical visit
Diagnosis of severe asthma for at least one year as defined by:
Treatment with guidelines-suggested medications for Global Initiative for Asthma (3) steps 4-5 asthma
Patients or their legal guardian, who voluntarily sign and date the informed consent form prior to study entry.

Criterios de exclusión

Patients with a diagnosis of chronic obstructive pulmonary disease or other chronic respiratory condition beyond severe asthma
An acute or chronic condition that, in the investigator's opinion, would limit the patient's ability to participate in this study Patients who are currently under a biologic therapy to treat their severe asthma

Ubicaciones

Research Site

Buenos Aires, Argentina

Research Site

Rosario, Argentina

Patrocinadores

PrincipalAstraZeneca

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

PREPARE STUDY: PRevalence of the Eosinophilic Phenotype A... | EligiMed